KR20160062166A - 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 - Google Patents

고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 Download PDF

Info

Publication number
KR20160062166A
KR20160062166A KR1020167012099A KR20167012099A KR20160062166A KR 20160062166 A KR20160062166 A KR 20160062166A KR 1020167012099 A KR1020167012099 A KR 1020167012099A KR 20167012099 A KR20167012099 A KR 20167012099A KR 20160062166 A KR20160062166 A KR 20160062166A
Authority
KR
South Korea
Prior art keywords
patient
antibody
pcsk9
ldl
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167012099A
Other languages
English (en)
Korean (ko)
Inventor
마리 바카라-디네
로렝스 베작
우메쉬 차우드하리
코린 하노텡
로버트 씨. 포디
윌리엄 제이. 새시엘라
대니얼 에이. 슈웨머 가이프
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Priority to KR1020227011822A priority Critical patent/KR20220048051A/ko
Publication of KR20160062166A publication Critical patent/KR20160062166A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
KR1020167012099A 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 Ceased KR20160062166A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227011822A KR20220048051A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US61/890,154 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US61/923,103 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US61/955,514 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US62/004,620 2014-05-29
US201462025104P 2014-07-16 2014-07-16
US62/025,104 2014-07-16
EP14306221.4 2014-07-31
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
US62/054,571 2014-09-24
EP14306584.5 2014-10-09
EP14306584 2014-10-09
PCT/US2014/060109 WO2015054619A2 (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011822A Division KR20220048051A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20160062166A true KR20160062166A (ko) 2016-06-01

Family

ID=52813751

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167012099A Ceased KR20160062166A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020227011822A Ceased KR20220048051A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020237026483A Ceased KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227011822A Ceased KR20220048051A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
KR1020237026483A Ceased KR20230119045A (ko) 2013-10-11 2014-10-10 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도

Country Status (14)

Country Link
US (1) US20150140002A1 (enExample)
EP (2) EP3689913B1 (enExample)
JP (2) JP6846931B2 (enExample)
KR (3) KR20160062166A (enExample)
CN (3) CN115154599A (enExample)
AU (2) AU2014331754B2 (enExample)
CA (1) CA2926942A1 (enExample)
EA (1) EA037526B1 (enExample)
ES (1) ES2914978T3 (enExample)
IL (1) IL244995B (enExample)
MX (3) MX373298B (enExample)
PL (2) PL3055333T4 (enExample)
TW (1) TWI669131B (enExample)
WO (1) WO2015054619A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2016248997B2 (en) * 2015-04-15 2019-03-07 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
EA201890519A1 (ru) * 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
US10600502B2 (en) * 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
WO2018200489A1 (en) 2017-04-25 2018-11-01 The Brigham And Women’S Hospital, Inc. Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
CN107090474A (zh) * 2017-05-22 2017-08-25 山东大学 一种腹主动脉瘤疾病动物模型的制备方法
WO2018228406A1 (zh) * 2017-06-14 2018-12-20 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
IL277127B2 (en) * 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
JP2023501745A (ja) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体及びその使用
JP2023506732A (ja) * 2019-12-10 2023-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
CN114277032A (zh) * 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) * 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途

Also Published As

Publication number Publication date
TWI669131B (zh) 2019-08-21
MX2022013172A (es) 2022-11-30
EP3055333A2 (en) 2016-08-17
IL244995B (en) 2019-12-31
ES2914978T3 (es) 2022-06-20
KR20230119045A (ko) 2023-08-14
WO2015054619A3 (en) 2015-06-04
EP3055333B1 (en) 2019-12-04
US20150140002A1 (en) 2015-05-21
JP6994484B2 (ja) 2022-02-04
PL3689913T3 (pl) 2022-07-04
EA037526B1 (ru) 2021-04-08
JP2016538248A (ja) 2016-12-08
AU2020203636A1 (en) 2020-06-25
JP6846931B2 (ja) 2021-03-24
CN105814085A (zh) 2016-07-27
IL244995A0 (en) 2016-05-31
CN115192704A (zh) 2022-10-18
MX2016004580A (es) 2016-12-08
WO2015054619A2 (en) 2015-04-16
AU2020203636B2 (en) 2023-05-18
TW201605475A (zh) 2016-02-16
KR20220048051A (ko) 2022-04-19
MX373298B (es) 2020-05-20
AU2014331754A1 (en) 2016-05-26
JP2019214594A (ja) 2019-12-19
WO2015054619A8 (en) 2016-03-31
PL3055333T3 (pl) 2020-06-01
CN115154599A (zh) 2022-10-11
EA201690754A1 (ru) 2016-10-31
EP3689913B1 (en) 2022-03-23
CA2926942A1 (en) 2015-04-16
EP3689913A1 (en) 2020-08-05
PL3055333T4 (pl) 2020-07-27
MX2020004023A (es) 2020-08-13
AU2014331754B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
AU2020203636B2 (en) Use of a PCSK9 inhibitor to treat hyperlipidemia
US12606638B2 (en) Dosing regimens for use with PCSK9 inhibitors
US20180296672A1 (en) Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy
KR20160132459A (ko) 심혈관 위험을 감소시키는 방법
KR20170028441A (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
US20150283236A1 (en) Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
AU2016308111A1 (en) Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
IL271456A (en) A pharmaceutical composition containing PCSK9 inhibitor for use in the treatment of hyperlipidemia
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA051213B1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190923

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210304

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211007

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210304

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211007

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210604

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190923

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220208

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220105

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211007

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210604

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210304

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190923

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220408

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220408

WITB Written withdrawal of application